Calithera Biosciences

NCT02000934

A Study of TAK-659 in Adult Participants With Advanced Solid Tumor and Lymphoma Malignancies

NCT02071862

Study of the Glutaminase Inhibitor CB-839 in Solid Tumors

NCT02071888

Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors

NCT02071927

Study of the Glutaminase Inhibitor CB-839 in Leukemia

NCT02197572

Effect of Sapanisertib (MLN0128) on the QTc Interval in Participants With Advanced Solid Tumors

NCT02834247

A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors

NCT02944435

A Comparative, Pharmacokinetic Study of CB-839 Capsule and Tablet Formulations in Healthy Adults

NCT03238651

A Study of TAK-659 as a Single Agent in Adult East Asian Participants With Non-Hodgkin Lymphoma (NHL)

NCT03370302

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of TAK-228 as Single Agent in Adult East Asian Participants With Advanced Nonhematological Malignancies

NCT03357627

A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma

NCT03359733

A Study to Evaluate the Effect of Food on the Pharmacokinetics (PK) of TAK-659 in Participants With Advanced Solid Tumor

NCT03338881

A Study to Assess Mass Balance, Pharmacokinetics (PK), and Metabolism of Orally Administered [14 C]-TAK-659 in Participants With Advanced Solid Tumor and/or Lymphoma Malignancies

NCT03772288

A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL)

NCT04279769

Study to Evaluate the Safety of CB-280 in Patients With Cystic Fibrosis

NCT04540965

Impact of a Histamine H2 Receptor Antagonist (H2RA) on the Pharmacokinetics (PK) of Telaglenastat in Healthy Subjects

NCT04607512

Study to Evaluate the ECG Effects of Telaglenastat in Healthy Adult Subjects